Neuland Laboratories Ltd. · NSE:NEULANDLAB
Neuland Laboratories — Q2 FY27 Earnings Presentation
38 slides from Neuland Laboratories's earnings presentation, Nov 3, 2026
Slide 1: Stock exchange filing cover letter
November 3, 2026 To BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, 25th Floor, Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Investors/Analys
Slide 2: Investor Presentation Q2FY27 & H1FY27
Neuland Laboratories Limited Investor Presentation Q2FY27 & H1FY27
Slide 3: Safe Harbour
SAFE HARBOUR Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Table of Contents
Table of Contents Q2FY27 Highlights Company Overview Business Strategy Our Businesses Shareholder Information Q2FY27 Company Business Our Shareholder Annexure Annexure Highlights Overview Strategy Businesses Information 3
Slide 5: Q2FY27 & H1FY27 Highlights
Q2FY27 & H1FY27 Highlights 4
Slide 6: Management Commentary
Management Commentary SAHARSH DAVULURI, CEO & MD “While we have experienced a dip in performance this quarter, H1 FY27 was largely in line with plan and our growth expectations remain intact for FY27 and the following year. Commercial CMS molecules continue to drive near-term growth, while strong RF
Slide 7: Q2FY27 Business Overview
Q2FY27 Business Overview CMS CMS revenues driven by commercial molecules. Growth in new projects orders which will be delivered over the course of this and next financial years. Traction from Innovators with peptides molecules in pipeline. GDS In Prime segment, Ezetimibe and Mirtazapine were the key
Slide 8: Q2FY27 Financial Highlights
Q2FY27 Financial Highlights Total Income EBITDA PAT EPS (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) PAT PAT Margin EBITDA EBITDA Margin 26.9% 22.7% 40.5% 18.7% 35.5% 165.6 30.4% 788.7 212.5 22.9% 11.2% 114.9 319.4 650.1 19.0% 9.0% 516.1 147.4 231.1 457.2 447.8 75.2 156.9 96.5 51.13 39.9 104.6 31.5 40.1 85 Q2FY
Slide 9: H1FY27 Financial Highlights
H1FY27 Financial Highlights Total Income EBITDA PAT* EPS (Rs. Cr) (Rs. Cr) 400.0 30.3% 35.0% (Rs. Cr) 17.9% 20.0% (Rs.) 18.0% 350.0 30.0% 24.4% 200.0 13.5% 16.0% 300.0 25.0% 14.0% 250.0 150.0 12.0% 20.0% 1107.2 154.7 335.6 198.5 200.0 10.0% 15.0% 100.0 816.7 8.0% 150.0 199.1 110.2 85.9 6.0% 10.0% 10
Slide 10: Key Balance Sheet Metrics
Key Balance Sheet Metrics Current Ratio ROCE% Fixed Asset Turnover Ratio Debt to Equity 0.12 32.8 3.1 0.10 0.10 0.10 0.10 2.4 26.1 2.7 2.2 2.6 24.3 2.1 2.4 2.1 2.3 21.3 1.7 17.9 FY23 FY24 FY25 FY26 H1FY27 FY23 FY24 FY25 FY26 H1FY27 FY23 FY24 FY25 FY26 H1FY27 FY23 FY24 FY25 FY26 H1FY27 Particulars (R
Slide 11: Key Operating Metrics Q2FY27
Key Operating Metrics Q2FY27 Segment revenue Top 10 & Top 5 Products Top 10 & Top 5 Customers Top 10% Top 5% Top 10 Top 5 Prime Specialty CMS Others 4% 6% 6% 6% 99% 98% 99% 8% 93% 92% 81% 96% 82% 94% 71% 83% 60% 53% 61% 68% 67% 71% 68% 62% 61% 57% 10% 11% 11% 8% 8% 26% 30% 22% 18% 18% Q2FY26 Q3FY26
Slide 12: CMS – Revenue Split & Number of Active Projects
CMS – Revenue Split & Number of Active Projects Rs. Cr YoY Movement No. of active CMS projects Q2 FY27 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg Commercial Grand Total API 15 13 13 5 4 9 59 Intermediate 2 10 7 8 3 10 40 639 411 Grand Total 17 23 20 13 7 19 99 32 41 H1FY26 H1FY27 Q2 FY26 Pre-Clinical P-1
Slide 13: Company Overview
Company Overview 12
Slide 14: Company Overview
Company Overview Manufacturing of generic Generic APIs non-exclusive APIs Established in Business 1984 verticals Contract development and 40 years in API manufacturing CDMO Services manufacturing of NCE API and development Total reactor volume of 12,32,000 Liters Facilities Inspected by Supported 4
Slide 15: Key Facts
Key Facts 40+ 1016+ 100+ 92% Years of experience DMFs Filed API across 10 diverse Revenue from exports worldwide therapeutic areas 80+ 77 1232 KL 2362 Countries Served Active US DMFs API Manufacturing Employees Capacity 14
Slide 16: Board Of Directors
Board Of Directors Dr. Davuluri D. Sucheth Rao D. Saharsh Rao Mr. Prasad Mr. Homi Rustam Rama Mohan Rao Executive Vice Chief Executive Officer Raghavan Menon Khusrokhan Executive Chairman Chairman & Managing Director Independent Independent Director Director Dr. Ravi Shankar Ms. Pallavi Joshi Mr. Su
Slide 17: Key Milestones
Key Milestones Our Journey 2019 2020 2021 2023 2024 2025 2026 Increased flow of projects $100 M+ revenue over 75 Unit – III Crossed INR 10 bn US FDA audit of US FDA audit of Unit-II New Peptide Facility operational from CMS Japan live CMS projects Commercialization 320 revenue Unit-I Capex investmen
Slide 18: Our Global Presence
Our Global Presence* EUROPE 63% APAC NORTH AMERICA 2% 31% BD office in Princeton, New Jersey Since 2004 JAPAN 1% BD office in Tokyo, Japan Since 2007 LATAM INDIA 1% 1% Headquarters in MENA Hyderabad, India 3 Manufacturing 1% Units Manufacturing and Development partner to customers in over 80 Countri
Slide 19: Manufacturing Facilities Overview
Manufacturing Facilities Overview UNIT - I UNIT - II UNIT - III Bonthapally, Hyderabad 262 kL Pashamylaram, Hyderabad 389 kL Gaddapotharam, Hyderabad 581 kL Year of 1986 1994 2017 Establishment Blocks Block - 1, 2, 3, 4, H, kL & S Block-1, 2, 3, FC, NMSM, Mini plant(A&B) Block - 1, 2, 4, 5, 6, 7 & 8
Slide 20: State-of-the-art R&D Centre
State-of-the-art R&D Centre Infrastructure Significant R&D achievements • 15 Development Labs with space • Several NCE APIs added in NDA or for expansion commercial stage drugs • 70 Fume hoods • Support for multiple APIs each year in • Analytical Labs Phase 2 and Phase 3 clinical candidates • Dedica
Slide 21: Regulatory Filings
Regulatory Filings 77 33 10 17 26 DMFs with Filings with Japanese China DMF Filings with USFDA Health Canada DMF filed filed KFDA Korea 28 293 ~500 32 1016+ Filings with ROW filings EUDMF filings CEPs received Filings till date TGA including across Germany, for different Turkey, Mexico, France, Pola
Slide 22: Financial Highlights FY2017-2026
Financial Highlights FY2017-2026 Rs. Cr FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 Total Income 588.9 533.7 670.3 766.6 953.0 953.2 1,200.9 1,571.1 1,497.3 2,053.1 EBITDA 106.9 54.6 61.4 105.3 162.5 144.3 281.1 474.5 342.8 603.4 EBITDA Margin 18.1% 10.2% 9.2% 13.7% 17.1% 1
Slide 23: Business Strategy
Business Strategy 22
Slide 24: Neuland Strategy Framework
Neuland Strategy Framework 04 Digitize to enable transparency, compliance, speed of decision making and ease of doing business 01 Invest in new technologies that are valued by our customers and help us differentiate vs. peers 05 Build a world-class talent pipeline and employee value proposition to e
Slide 25: Our Businesses
Our Businesses 24
Slide 26: Generic APIs (GDS)
Generic APIs (GDS) • We are a preferred service provider in the • API manufacturing heritage of over 40 years manufacturing of Active Pharmaceutical Ingredients (APIs) • Flexible 100g to hundreds of tons capacity • Have developed processes for over 100 • Non-competitive advantage (does not APIs with
Slide 27: CDMO Services (CMS)
CDMO Services (CMS) cGMP manufacturing of RSMs/KSMs/Intermediates and APIs for clinical trials and commercial supply Chemistry & manufacturing capabilities Synthetic portion of Carbohydrate Process fermented molecules chemistry optimization IND/NDA filing Deuterated Cyclic and support molecules PEGy
Slide 28: Shareholder Information
Shareholder Information 27
Slide 29: Shareholding Details
Shareholding Details Share Information (as on 30th September 2026) NSE Ticker NEULANDLAB BSE Ticker 524558 Others Market Cap (Rs. In Cr) 27,446.53 30% % free float 67.74 Promoters 32% Free Float Market Cap (Rs. In Cr) 18,592.28 Shares Outstanding 12,829,889 3M Average Daily Traded Volume FII 63,317
Slide 30: Annexure
Annexure 29
Slide 31: Profit & Loss Snapshot (Standalone)
Profit & Loss Snapshot (Standalone) Particulars Q2 FY 27 Q2 FY 26 YoY% Q1 FY 27 QoQ% H1 FY 27 H1 FY 26 YoY% (Rs Cr) Total Income 457.15 516.07 -11.4% 650.07 -29.7% 1,107.22 816.68 35.6% EBITDA 104.55 156.92 -33.4% 231.07 -54.8% 335.62 199.07 68.6% EBITDA Margin 22.9% 30.4% -754 BPS 35.5% -1267 BPS 3
Slide 32: Revenue & PBT trend
Revenue & PBT trend Rs Cr Revenue 789 650 516 421 444 448 457 415 395 390 402 365 336 294 315 301 270 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 PBT* Rs Cr 287 198 121 130 128 129 110 104 84 92 54 68 53 39 49 39 17 Q2FY23 Q3
Slide 33: Vision and Values
We are creating a healthier world through sustainable practices, trusted partnerships, and agile collaboration Vision and Values (— Innovation Innovative in everything we do (% Transparency Transparent and open in our communication (a Accountability Accountable for our delivery g Empathy Empathy in
Slide 34: Sustainability Framework: ESG commitment & Goals (1/3)
Sustainability Framework: ESG commitment & Goals (1/3) Environment Focus area Our commitments Key ESG goals (included in Balance Scorecard) • FY 2033-34: 58.8%* reduction in Scope 1 & 2 emissions (FY 2023-24 baseline) • Reduce both direct (Scope 1 & 2) and indirect • FY 2049-50: Achieve Net Zero in
Slide 35: Sustainability Framework: ESG commitment & Goals (2/3)
Sustainability Framework: ESG commitment & Goals (2/3) Social Focus area Our commitments Key ESG goals (included in Balance Scorecard) • Maintain Zero Fatality Occupational health • Strive for zero harm environment across all • Maintain Nil Long-term Injury and Safety operations • Frequency Rate (LT
Slide 36: Sustainability Framework: ESG commitment & Goals (3/3)
Sustainability Framework: ESG commitment & Goals (3/3) Governance Focus area Our commitments Key ESG goals (included in Balance Scorecard) Product Quality and Regulatory • Strong Quality Culture • Maintain 100% compliance across GMP operations compliance Business • Build resilience through enterpris
Slide 37: Glossary
Glossary Term Description Term Description Any substance that is intended for incorporation into a finished drug Drugs (small or large molecule) under development by a Pipeline drugs Active Pharmaceutical product and is intended to furnish pharmacological activity or other manufacturer Ingredient (A
Slide 38: Thank you
Thank you For further information contact IR Desk Neuland Labs Contact: +91 40 6761 1600 Email: [email protected] Runjhun Jain / Minakshi Machutre EY IR Contact: +91 22 6192 2000 Email: [email protected] / [email protected]